Vatalanib in Treating Patients With Metastatic Cutaneous Melanoma That Cannot be Removed by Surgery
Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Vatalanib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth and by blocking blood flow to the tumor.
PURPOSE: This phase II trial is studying how well vatalanib works in treating patients with
metastatic cutaneous melanoma that cannot be removed by surgery.
Phase:
Phase 2
Details
Lead Sponsor:
Cambridge University Hospitals NHS Foundation Trust